Q3 2024 delivered strong EBITDA and improved gross margin, despite soft revenue growth due to lower China sales. fCAL turbo sales surged 76% year-over-year, and NT-proBNP assay advanced in clinical evaluation with a new patent granted.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.